News Posts List
Cancer Genetics Announces Compelling Diagnostic Sensitivity (99%) and Accuracy (93%) for Its Patent-Protected Genomic Kidney Cancer Test
03/06/2014
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI") announced today the results of a collaborative study conducted with The Cleveland Clinic to validate CGI's kidney cancer microarray test.
Hollywood's Denise Richards Promotes Kidney Cancer Awareness Month
03/06/2014
March is Kidney Cancer Awareness Month and the Kidney Cancer Association (KCA) and its nearly 90,000 members in more than 100 countries are celebrating by honoring the many collaborators who have helped to make it the largest organization of its kind.
ACA Causing Some Kidney Cancer Patients to Lose Health Coverage
03/05/2014
Virginia Cancer Patient's Insurance Terminated Due To ObamaCare
Neurologic status at surgery affects metastatic spinal renal cell carcinoma survival
02/28/2014
Neurological status at surgery, the grade of the original nephrectomy specimen and activity of the systemic disease were factors found to influence a patient’s survival after spine surgery for metastatic spinal renal cell carcinoma...
Calithera begins phase I study of CB-839 in patients with advanced solid tumours
02/27/2014
CB-839 is a potent, selective, orally bioavailable inhibitor of glutaminase that interferes with tumor metabolism and blocks cancer cell growth and survival.
Transgene Announces Plans for a Phase 1b/2 Trial with Pexa-Vec in Advanced Solid Tumors
02/26/2014
The Phase 1b/2 trial will evaluate Pexa-Vec in combination with metronomic cyclophosphamide, a drug used in combination with other therapies to treat a wide variety of cancers.
Perioperative blood transfusion worsens kidney cancer patients’ survival
02/26/2014
Receipt of a blood transfusion significantly reduced cancer-specific (68 vs 92%) and recurrence-free survival (63 vs 88%) at 5-years’ follow-up on univariate analysis.
Forty-nine-month survival in a metastatic renal cell carcinoma patient across six lines of targeted therapy
02/26/2014
The survival and prognosis of mRCC patients may thus be significantly improved with the suitable use of newer targeted agents.
The only top 10 cancer where survival rates are falling
02/26/2014
Yet, it is still a cancer that is hardly ever talked about.
Partial nephrectomy may offer younger renal cancer patients survival advantage
02/26/2014
Overall survival at 10 years was 94.0% with nephron-sparing surgery and 89.7% with radical nephrectomy, with a hazard ratio of 0.50.
News Feed